Stephen Waldek

7.4k total citations · 1 hit paper
57 papers, 4.5k citations indexed

About

Stephen Waldek is a scholar working on Physiology, Rheumatology and Epidemiology. According to data from OpenAlex, Stephen Waldek has authored 57 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Physiology, 17 papers in Rheumatology and 16 papers in Epidemiology. Recurrent topics in Stephen Waldek's work include Lysosomal Storage Disorders Research (37 papers), Glycogen Storage Diseases and Myoclonus (16 papers) and Trypanosoma species research and implications (15 papers). Stephen Waldek is often cited by papers focused on Lysosomal Storage Disorders Research (37 papers), Glycogen Storage Diseases and Myoclonus (16 papers) and Trypanosoma species research and implications (15 papers). Stephen Waldek collaborates with scholars based in United Kingdom, United States and France. Stephen Waldek's co-authors include Dominique P. Germain, William R. Wilcox, Maryam Banikazemi, David G. Warnock, Robert J. Desnick, Philip Lee, Alberto Ortíz, Roberta Lemay, Christoph Wanner and João Paulo Oliveira and has published in prestigious journals such as Annals of Internal Medicine, Journal of the American Society of Nephrology and The American Journal of Human Genetics.

In The Last Decade

Stephen Waldek

57 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fabry disease revisited: Management and treatment recommendations for adult patients

2018 401 citations Alberto Ortíz, Dominique P. Germain et al. Molecular Genetics and Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Waldek United Kingdom	31	3.9k	1.8k	1.3k	1.1k	1.0k	57	4.5k
Uma Ramaswami United Kingdom	34	3.0k 0.8×	1.4k 0.8×	1.0k 0.8×	734 0.7×	722 0.7×	115	4.0k
Marco Spada Italy	28	1.6k 0.4×	700 0.4×	716 0.6×	428 0.4×	415 0.4×	132	3.1k
Saskia M. Rombach Netherlands	18	1.6k 0.4×	759 0.4×	378 0.3×	460 0.4×	499 0.5×	36	1.8k
Olivier Lidove France	27	1.3k 0.3×	716 0.4×	578 0.4×	243 0.2×	327 0.3×	134	2.2k
Albina Nowak Switzerland	21	872 0.2×	467 0.3×	209 0.2×	219 0.2×	273 0.3×	94	1.5k
Sandra Sirrs Canada	22	700 0.2×	337 0.2×	249 0.2×	186 0.2×	208 0.2×	79	1.6k
Eleonora Riccio Italy	23	672 0.2×	271 0.1×	208 0.2×	146 0.1×	175 0.2×	114	1.7k
Pamela Arn United States	20	661 0.2×	266 0.1×	809 0.6×	260 0.2×	65 0.1×	36	1.8k
Tarekegn Geberhiwot United Kingdom	24	728 0.2×	305 0.2×	180 0.1×	88 0.1×	212 0.2×	89	1.5k
Karim Chikh France	21	543 0.1×	220 0.1×	77 0.1×	207 0.2×	144 0.1×	49	1.5k

Countries citing papers authored by Stephen Waldek

Since Specialization

Citations

This map shows the geographic impact of Stephen Waldek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Waldek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Waldek more than expected).

Fields of papers citing papers by Stephen Waldek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Waldek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Waldek. The network helps show where Stephen Waldek may publish in the future.

Co-authorship network of co-authors of Stephen Waldek

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Waldek. A scholar is included among the top collaborators of Stephen Waldek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Waldek. Stephen Waldek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Banikazemi, Maryam, Jan Bultas, Stephen Waldek, et al.. (2020). Agalsidase-Beta Therapy for Advanced Fabry Disease. Annals of Internal Medicine. 146(2). 1 indexed citations

Germain, Dominique P., Eva Brand, Alessandro P. Burlina, et al.. (2018). Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Molecular Genetics & Genomic Medicine. 6(4). 492–503. 81 indexed citations

Ortíz, Alberto, Dominique P. Germain, Robert J. Desnick, et al.. (2018). Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular Genetics and Metabolism. 123(4). 416–427. 401 indexed citations breakdown →

Hopkin, Robert J., Gustavo Cabrera, Joel Charrow, et al.. (2016). Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Molecular Genetics and Metabolism. 119(1-2). 151–159. 41 indexed citations

Sutherland, Adam & Stephen Waldek. (2015). It is time to review how unlicensed medicines are used. European Journal of Clinical Pharmacology. 71(9). 1029–1035. 15 indexed citations

Waldek, Stephen & Sandro Feriozzi. (2014). Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy?. BMC Nephrology. 15(1). 72–72. 75 indexed citations

Tol, Linda van der, Einar Svarstad, Alberto Ortíz, et al.. (2014). Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. Molecular Genetics and Metabolism. 114(2). 242–247. 44 indexed citations

Wilcox, William R., Gabor E. Linthorst, Dominique P. Germain, et al.. (2011). Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry. Molecular Genetics and Metabolism. 105(3). 443–449. 57 indexed citations

Waldek, Stephen, Edward H. Giannini, Atul Mehta, et al.. (2010). 140. A validated disease severity scoring system for Fabry disease. Molecular Genetics and Metabolism. 99(2). S37–S37. 4 indexed citations

10.

Atkinson, Paul, Raj Kumar Sharma, Paul R. Kalra, et al.. (2009). Predictive value of myocardial and coronary imaging in the long-term outcome of potential renal transplant recipients. International Journal of Cardiology. 146(2). 191–196. 20 indexed citations

11.

Schiffmann, Raphael, Stephen Waldek, Ariela Benigni, & Christiane Auray‐Blais. (2009). Biomarkers of Fabry Disease Nephropathy. Clinical Journal of the American Society of Nephrology. 5(2). 360–364. 56 indexed citations

12.

Tavakoli, Mitra, Andrew Marshall, Lorraine Thompson, et al.. (2009). Corneal confocal microscopy: A novel noninvasive means to diagnose neuropathy in patients with fabry disease. Muscle & Nerve. 40(6). 976–984. 9 indexed citations

13.

Oliveira, João Paulo, et al.. (2008). Splenomegaly, hypersplenism and peripheral blood cytopaenias in patients with classical Anderson–Fabry disease. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 453(3). 291–300. 4 indexed citations

14.

Waldek, Stephen, et al.. (2008). MILK ALKALI SYNDROME ASSOCIATED WITH EXCESSIVE INGESTION OF RENNIE^®: CASE REPORTS. Journal of Renal Care. 34(2). 64–67. 5 indexed citations

15.

Ortíz, Alberto, João Paulo Oliveira, Stephen Waldek, et al.. (2008). Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrology Dialysis Transplantation. 23(5). 1600–1607. 157 indexed citations

16.

Banikazemi, Maryam, Jan Bultas, Stephen Waldek, et al.. (2007). Agalsidase-Beta Therapy for Advanced Fabry Disease. Annals of Internal Medicine. 146(2). 77–86. 418 indexed citations

17.

Germain, Dominique P., Stephen Waldek, Maryam Banikazemi, et al.. (2007). Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease. Journal of the American Society of Nephrology. 18(5). 1547–1557. 332 indexed citations

18.

Young, E., Kevin Mills, C. Phillip Morris, et al.. (2005). Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Paediatrica. 94(0). 51–54. 68 indexed citations

19.

Waldek, Stephen, et al.. (1992). Estimation of Renal Tubular Secretion in Man, in Health and Disease, Using Endogenous N-1-Methylnicotinamide. The Nephron journals/Nephron journals. 60(1). 12–16. 28 indexed citations

20.

Morton, A. Ross, Alan Holmes, & Stephen Waldek. (1986). The kidney in myeloma. BMJ. 292(6516). 339.5–340. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact